ACT Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

ACT Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$97K	Hold	90,000	–	–	0.13%	49
2022 Q2	$153K	Hold	90,000	–	–	0.21%	43
2022 Q1	$185K	Hold	90,000	–	–	0.2%	52
2021 Q4	$338K	Hold	90,000	–	–	0.24%	54
2021 Q3	$465K	Buy	+90,000	New	+$404K	0.24%	62

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACT Capital Management's ADAP Position: Q3 2022 in Review

ACT Capital Management held its Adaptimmune Therapeutics (ADAP) position steady in Q3 2022 at 90,000 shares worth $97K. The position accounts for 0.13% of the portfolio, ranked #49.

ACT Capital Management first reported a position in ADAP in Q3 2021 and has held it in 5 quarters since. The position peaked at $465K in Q3 2021. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

ACT Capital Management held 90,000 shares of Adaptimmune Therapeutics worth $97K as of Q3 2022.
ACT Capital Management left its Adaptimmune Therapeutics share count unchanged in Q3 2022.
Adaptimmune Therapeutics made up 0.13% of ACT Capital Management's portfolio in Q3 2022, its #49 holding.
ACT Capital Management first reported a position in Adaptimmune Therapeutics in Q3 2021 and has held it in 5 quarters since.
ACT Capital Management's Adaptimmune Therapeutics position peaked at $465K in Q3 2021.
68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.